Elevated circulating levels of matrix metalloproteinase-9 in type 1 diabetic patients with and without retinopathy

Clinica Chimica Acta

Volumn 367, Issue 1-2, 2006, Pages 103-107

  Jacqueminet, S ^a   Ben Abdesselam, O ^a   Chapman, M J ^a   Nicolay, N ^b   Foglietti, M J ^a   Grimaldi, A ^a   Beaudeux, J L ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSERM   (France)

Author keywords

Blood measurement; Diabetes mellitus; Extracellular matrix; Metalloproteinase; Retinopathy

Indexed keywords

BIOLOGICAL MARKER; GELATINASE B; INSULIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE DURATION; ENZYME IMMUNOASSAY; FEMALE; HUMAN; INDEPENDENT VARIABLE; INSULIN DEPENDENT DIABETES MELLITUS; LOGISTIC REGRESSION ANALYSIS; MALE; PATIENT SELECTION; PRIORITY JOURNAL;

ADULT; AGED; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 1; DIABETIC RETINOPATHY; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 33646472808     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2005.11.029     Document Type: Article

References (40)

1. Williams R., Airey M., Baxter H., Forrester J., Kennedy-Martin T., and Girach A. Epidemiology of diabetic retinopathy and macular oedema: a systematic review. Eye 18 (2004) 963-983
2. Joussen A.M., Poulaki V., Le M.L., et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 18 (2004) 1450-1452
3. Adamis A.P., Aiello L.P., and D'Amato R.A. Angiogenesis and ophthalmic disease. Angiogenesis 3 (1999) 9-14
4. Hiscott P., Waller H.A., Grierson I., Butler M.G., and Scott D.L. The extracellular matrix of reparative tissue in the vitreous: fibrinectin production in proliferative diabetic retinopathy membranes. Eye 7 (1993) 288-292
5. Beaudeux J.L., Giral P., Bruckert E., Foglietti M.J., and Chapman M.J. Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives. Clin Chem Lab Med 42 (2004) 121-131
6. Visse R., and Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92 (2003) 827-839
7. Pepper M.S. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 21 (2001) 1104-1117
8. Gomez D.E., Alonso D.F., Yoshiji H., and Thorgeirsson U.P. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 74 (1997) 111-122
9. Sierevogel M.J., Pasterkamp G., De Kleinj D.P., and Strauss B.H. Matrix metalloproteinases: a therapeutic target in cardiovascular disease. Curr Pharm Des 9 (2003) 1033-1040
10. Tsilibary E.C. Microvascular basement membranes in diabetes mellitus. J Pathol 200 (2003) 537-546
11. Suzuki D., Yagame M., Kim Y., Sakai H., and Mauer M. Renal in situ hybridization studies of extracellular matrix related molecules in type 1 diabetes mellitus. Nephron 92 (2002) 564-572
12. Del Prete D., Anglani F., Forino M., et al. Down-regulation of glomerul matrix metalloproteinase-2 gene in human NIDDM. Diabetologia 40 (1997) 1449-1454
13. Nakamura T., Fukui M., Ebihara I., Osada S., Tomino Y., and Koide H. Abnormal gene expression of matrix metalloproteinases and their inhibitor in glomeruli from diabetic rats. Rev Physiol Biochem Pharmacol 17 (1994) 316-325
14. Ebihara I., Nakamura T., Shimada N., and Koide H. Increased serum metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus. Am J Kidney Dis 32 (1998) 544-550
15. Noda K., Ishida S., Inoue M., et al. Production and activation of matrix metalloproteinase-2 in proliferative diabetic retinopathy. Invest Ophthalmol Visual Sci 44 (2003) 2163-2170
16. Jin M., Kashiwagi K., Iizuka Y., Tanaka Y., Imai M., and Tsukahara S. Matrix metalloproteinases in human diabetic and nondiabetic vitreous. Retina 21 (2001) 28-33
17. Takahashi H., Akiba K., Noguchi T., et al. Matrix metalloproteinase activity is enhanced during corneal wound repair in high glucose condition. Curr Eye Res 21 (2000) 608-615
18. Saghizadeh M., Brown D.J., Castellon R., et al. Overexpression of matrix metalloproteinase-3 in human diabetic corneas: a possible mechanism of basement membrane and integrin alterations. Am J Pathol 158 (2001) 723-734
19. Salzmann J., Limb G.A., Khaw P.T., et al. Matrix metalloproteinases and their natural inhibitors in fibrovascular membranes of proliferative diabetic retinopathy. Br J Ophthalmol 84 (2000) 1091-1096
20. Massin P., Angioi-Duprez K., Bacin F., et al. Recommendations of the ALFEDIAM (French association for the study of diabetes and metabolic diseases) for the screening and surveillance of diabetic retinopathy. J Fr Ophtalmol 20 (1997) 302-310
21. Maxwell P.R., Timms P.M., Chandran S., and Gordon D. Peripheral blood level alterations of TIMP-1, MMP-2 and MMP-9 in patients with type 1 diabetes. Diabet Med 18 (2001) 777-7780
22. Ishimura E., Nishizawa Y., Shoji S., and Mori H. Serum type III, IV collagens and TIMP in patients with type II diabetes mellitus. Life Sci 58 (1996) 1331-1337
23. Dandona P., Ghanim H., Aljada A., Bandyopadhyay A., Mohanty P., and Chaudhuri A. Insulin suppresses serum concentration of vascular endothelial growth factor and matrix metalloproteinase-9. Diabetes Care 26 (2003) 3310-3314
24. Aljada A., Ghanim H., Mohanty P., Syed T., Bandyopadhyay A., and Dandona P. Glucose intake induces an increase in activator protein 1 and early growth response 1 binding activities, in the expression of tissue factor and matrix metalloproteinase in mononuclear cells, and in plasma tissue factor and matrix metalloproteinase concentrations. Am J Clin Nutr 80 (2004) 51-57
25. Uemura S., Matsushita H., Li W., et al. Diabetes mellitus enhances vascular matrix metallorpoteinase activity: role of oxidative stress. Circ Res 88 (2001) 1291-1298
26. Beaudeux J.L., Giral P., Bruckert E., Bernard M., Foglietti M.J., and Chapman M.J. Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 as potential markers of carotid atherosclerosis in infraclinical hyperlipidemia. Atherosclerosis 169 (2003) 139-146
27. Kuzuya M., and Iguchi A. Role of matrix metalloproteinases in vascular remodelling. J Atheroscler Thromb 10 (2003) 275-282
28. Creager M.A., Lüscher T.F., Cosentino F., and Beckman J.A. Diabetes and vascular disease: pathology, clinical consequences, and medical therapy: Part I. Circulation 108 (2003) 1527-1532
29. Lüscher T.F., Creager M.A., Beckman J.A., and Cosentino F. Diabetes and vascular disease: pathology, clinical consequences, and medical therapy: part II. Circulation 108 (2003) 1655-1661
30. Kadoglou N.P., Daskalopoulou S.S., Perrea D., and Liapis C.D. Matrix metalloproteinases and diabetic vascular complication. Angiology 56 (2005) 173-189
31. McLenan S.V., Fisher E., Martell S.Y., et al. Effects of glucose on matrix metalloproteinase and plasmin activities in mesangial cells: possible role in diabetic nephropathy. Kidney Inter Suppl 77 (2000) 81-87
32. Khasigov P.Z., Ktzoeva S.A., Gatagonova T.M., Tareeva I.E., Grachev S.V., and Berezov T.T. Role of matrix metalloproteinases in development of diabetic nephropathy. Biochemistry 65 (2000) 519-524
33. Zaoui P., Cantin J.F., Alimardani-Bessette M., et al. Role of metalloproteases and inhibitors in the occurrence and progression of diabetic renal lesions. Diabetes Metab 26 (2000) 25-29
34. Seung Won L., Kyong Eun S., Dong Sun S., et al. Alterations in peripheral blood levels of TIMP-1, MMP-2, and MPP-9 in patients with type-2 diabetes. Diabetes Res Clin Pract 69 (2005) 175-179
35. Giebel S.J., Menicucci G., McGuire P.G., and Das A. Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier. Lab Invest 85 (2005) 597-607
36. Grant M.B., Caballero S., Tarnuzzer R.W., et al. Matrix metalloproteinase expression in human retinal microvascular cells. Diabetes 47 (1998) 1311-1317
37. Kosano H., Okano T., Katsura Y., et al. ProMMP-9 (92 kDa gelatinase) in vitreous fluid of patients with proliferative diabetic retinopathy. Life Sci 64 (1999) 2307-2315
38. Das A., McGuire P.G., Eriqat C., et al. Human diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes. Invest Ophthalmol Vis Sci 40 (1999) 809-813
39. Gardner T.W., Antonetti D.A., Barber A.J., LaNoue K.F., and Nakamura M. New insights into the pathophysiology of diabetic retinopathy: potential cell-specific therapeutic targets. Diabetes Technol Ther 2 (2000) 601-608
40. Ferroni P., Basili S., Martini F., et al. Serum metalloproteinase 9 levels in patients with coronary artery disease: a novel marker of inflammation. J Investig Med 51 (2003) 295-300